B3GNT2 and melanoma: Our screen identifies four candidate genes (CD274 (PD-L1), MCL1, JUNB, and B3GNT2) that, upon upregulation, enable human melanoma cells to evade T cell killing in diverse cancer cell types and mouse xenografts.